Pulmonary Drug Delivery of Budesonide in the Form of Inhalable Microspheres

Objectives: Chronic Obstructive Pulmonary Disease (COPD) is a major healthcare issue that is rising and expected to increase in day-to-day life. Our research work focused on developing Dry Powder Inhaler (DPI) microspheres that deliver medication in the form of dry powder into the lungs. Budesonide was used as a drug along with Polycaprolactone which is a biodegradable and biocompatible polymer used in the formulation of microspheres. Due to its non-toxicity with many drugs, it is suitable for controlled release. Materials and Methods: The microspheres were formulated using solvent evaporation technique and evaluation parameters such as size, shape, drug loading, and entrapment efficiency for better patient compliance and treatment were performed. Results: The microsphere had particle size ranging from 1 μm-5 μm, within the inhalable range. The morphological study showed a smooth surface area with spherical-shaped particles. The particles were monodispersed with PDI less than 0.5. The % drug release was found to be 95.3% after 48 hr showing sustained drug release from Polycaprolactone microspheres. The in vivo study suggested that the given formulation effectively inhibited the LPS-induced toxicity in a dose-dependent fashion and proved to be anti-inflammatory. Conclusion: Budesonide inhalable microsphere of Polycaprolactone was proven to be beneficial without any toxicity for the treatment of coronary obstructive pulmonary technique.